Dyne Therapeutics has announced a significant amendment to its non-dilutive senior secured term loan facility with Hercules Capital, providing an additional up to $125 million in borrowing capacity. This includes $50 million funded immediately and a further $75 million that can be accessed upon meeting specific milestones. The funding strengthens Dyne’s financial position as it advances its clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), with potential U.S. launches expected in the next two years. This partnership demonstrates Hercules Capital’s ongoing commitment to supporting innovative life sciences companies at pivotal stages of development.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://investingnews.com/dyne-therapeutics-announces-expanded-debt-facility-of-up-to-400-million-with-hercules-capital-inc/
